[go: up one dir, main page]

MX2024003028A - Derivados de 6 aza quinolina y usos relacionados. - Google Patents

Derivados de 6 aza quinolina y usos relacionados.

Info

Publication number
MX2024003028A
MX2024003028A MX2024003028A MX2024003028A MX2024003028A MX 2024003028 A MX2024003028 A MX 2024003028A MX 2024003028 A MX2024003028 A MX 2024003028A MX 2024003028 A MX2024003028 A MX 2024003028A MX 2024003028 A MX2024003028 A MX 2024003028A
Authority
MX
Mexico
Prior art keywords
aza
compounds
quinoline derivatives
related uses
methods
Prior art date
Application number
MX2024003028A
Other languages
English (en)
Inventor
Fernando Padilla
Pui Yee Ng
Ivan Jewett
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Publication of MX2024003028A publication Critical patent/MX2024003028A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a compuestos de la Fórmula (0): (ver Fórmula); y sales y estereoisómeros de estos farmacéuticamente aceptables. La presente descripción también se refiere a métodos para preparar los compuestos, composiciones que comprenden los compuestos y métodos para usar los compuestos, por ejemplo, en el tratamiento del cáncer.
MX2024003028A 2021-09-10 2022-09-09 Derivados de 6 aza quinolina y usos relacionados. MX2024003028A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163242845P 2021-09-10 2021-09-10
US202263351158P 2022-06-10 2022-06-10
PCT/US2022/076164 WO2023039505A1 (en) 2021-09-10 2022-09-09 6-aza-quinoline derivatives and related uses

Publications (1)

Publication Number Publication Date
MX2024003028A true MX2024003028A (es) 2024-03-26

Family

ID=83688653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003028A MX2024003028A (es) 2021-09-10 2022-09-09 Derivados de 6 aza quinolina y usos relacionados.

Country Status (10)

Country Link
US (1) US20250017914A1 (es)
EP (1) EP4399210A1 (es)
JP (1) JP2024533380A (es)
KR (1) KR20240099171A (es)
AU (1) AU2022342182A1 (es)
CA (1) CA3229293A1 (es)
IL (1) IL310931A (es)
MX (1) MX2024003028A (es)
TW (1) TW202330517A (es)
WO (1) WO2023039505A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025536257A (ja) * 2022-10-14 2025-11-05 ブラック ダイアモンド セラピューティクス，インコーポレイティド イソキノリンまたは６－ａｚａ－キノリン誘導体を使用してがんを治療する方法
WO2025226822A2 (en) * 2024-04-24 2025-10-30 Black Diamond Therapeutics, Inc. Forms and salts of 6-aza-quinoline derivatives and related uses
CN121181427A (zh) * 2025-11-25 2025-12-23 天津楷特药业有限公司 一种苯并环酮甲酸酯类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20100197688A1 (en) * 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
CN103261167B (zh) * 2010-12-17 2016-05-04 霍夫曼-拉罗奇有限公司 取代的6，6-稠合含氮杂环化合物及其用途
US9187474B2 (en) * 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
CA3198943A1 (en) * 2020-11-18 2022-05-27 Daniel L. Flynn Gcn2 and perk kinase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
IL310931A (en) 2024-04-01
AU2022342182A1 (en) 2024-03-07
TW202330517A (zh) 2023-08-01
EP4399210A1 (en) 2024-07-17
WO2023039505A1 (en) 2023-03-16
CA3229293A1 (en) 2023-03-16
JP2024533380A (ja) 2024-09-12
KR20240099171A (ko) 2024-06-28
US20250017914A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
ECSP22077299A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
CL2023003275A1 (es) Inhibidores alostéricos de la cromenona de la fosfoinositida 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2023013987A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
CL2024001346A1 (es) Agonistas inversos del pparg y usos de los mismos
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
ECSP23091202A (es) Moduladores de trex1
CL2025001366A1 (es) Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa
CL2023003168A1 (es) Moduladores de trex1
MX2023011518A (es) Compuestos heterocíclicos novedosos y sus usos.
MX2024012198A (es) Compuestos y metodos para tratar canceres
MX2024013841A (es) Derivados de pirazina y usos de estos
CU20200020A7 (es) Composición farmacéutica que comprende abx196
CL2025002792A1 (es) Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores
MX2024013840A (es) Derivados de pirazina y usos de los mismos
DOP2025000212A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
AR134062A1 (es) Inhibidores de ras y sus métodos de uso
AR133189A1 (es) Inhibidores de triazolo wrn
CO2025006324A2 (es) Compuestos tricíclicos